

Longitudinal Assessment of Neuropsychological Functioning in Children with Acute The world's childhood cancer experts Lymphoblastic Leukemia (ALL) Treated on AALL1 131: A Report from the Children's Oncology Group



Kristina K. Hardy¹, Naomi Winick², Christina Sharkey³, Anthony R. Gioia¹, Michael Burke⁴, Wanda Salzer⁵, Mignon Loh⁶, Robert B. Noll⁷, Leanne Embry⁸ ¹Children's National Health System, ²University of Texas Southwestern, ³Oklahoma State University, ⁴Medical College of Wisconsin, ⁵United State Army Medical Research and Material Command ⁶University of California San Francisco, ⁷University of Pittsburgh Medical Center, ⁸University of Texas Health Science Center

NEUROCOGNITIVE OUTCOMES IN ALL

- 20-40% of ALL survivors experience cognitive decline
- Domains of particular risk
- attention
- working memory
- processing speed
- executive functioning
- **Unanswered questions**
 - What is the earliest point at which problems can be detected?
 - How can we predict who will have problems?
 - How many children have significant difficulties?

AALL1131 RESEARCH STRATEGY

- Maximize ability to obtain a large, representative sample of HR-ALL patients with multiple data points over time
- Minimize burden on participants and institutions
- Use brief, easy-to-administer measures given frequently during therapy

AALL1131: NEUROCOGNITIVE OBJECTIVES

- AIM 1: To determine if the prevalence of cognitive deficits in children (ages 6-11) with HR-ALL is significantly higher than the normative population
- AIM 2: To determine if there are significant declines in neurocognitive functioning in children with HR-ALL

PARTICIPANTS

- Children enrolled on the COG High Risk B-precursor ALL trial (AALL1131) aged 6 – 11 years at time of diagnosis.
- Exclusion criteria: premorbid neurodevelopmental disorder, or significant motor, auditory, or visual impairment.

FIGURE 1: Cognitive assessment strategy Girls complete **Boys complete** therapy therapy Year 2 Diagnosis Year 1 Year 4 Year 5 Monitoring Monitoring Monitoring Monitoring Monitoring Screening Screening Screening Monitoring Battery: Screening Battery: CogState: 20 minutes ALTE07C1: 60-90 minutes Parent report: 10 minutes Parent report: 20 minutes Assessed in clinic Assessed by psychologist

MEASURES: Monitoring battery

- CogState Computerized assessment of reaction time, sustained attention, working memory, and executive functioning
- **BRIEF** Parent-completed paper-andpencil measure of children's impairments in executive functioning

Fig 2: Identification task. Children push the "yes" button if the card is red, and the "no" button if it is not red.

RESULTS

- 376 participants have been enrolled (52% male, Mean age at diagnosis = 9.20
- Data collection rates range from 78% to 94% across time points
- 85% of participants are remaining on study over time

FIGURE 3: Abnormal attention scores* by age at diagnosis Aged 6-8 35 30 -Aged 9-11 25 20 *Abnormal scores on the 15 CogState battery are defined as > 85 (> 1.5 SD below the mean) Main 2 Main 4 Main 6 Main $10/1 \, yr$ FIGURE 4: Abnormal scores* over time Sustained Attn Reaction Time Parent-reported Norking Memory

CONCLUSION

- Early identification of cognitive difficulties may allow for targeted intervention at the earliest possible time point.
- Screening battery data will allow us to better understand intellectual outcomes and adaptive impairments and their relation to earlier deficits as identified by the Monitoring battery.